Abstract
All adolescents 11-18 years of age without contraindications should receive two doses of meningococcal conjugate vaccine (abbreviations: MCV4, MenACWY; trade names: Menactra®, Menveo®), routinely given at 11 or 12 years of age and a booster at 16 years of age. Adolescents who receive a first dose after their 16th birthday do not need a booster dose unless they become at increased risk for meningococcal disease. Vaccination to prevent meningococcal disease is also recommended for all persons starting at 9 months of age who are at increased risk for meningococcal disease (such as travelers to hyperendemic or epidemic countries; those with asplenia; or those with persistent complement component deficiency). Serogroup B meningococcal vaccine (trade names: Trumenba®, Bexsero®) is recommended for all persons starting at 10 years of age who are at increased risk for serogroup B meningococcal disease (such as those with persistent complement component deficiencies; those with anatomic or functional asplenia; microbiologists routinely exposed to N. meningitides; and anyone identified to be at increased risk during an outbreak of serogroup B meningococcal disease). Adolescents and young adults aged 16–23 years may also receive this vaccine, even if they are not at increased risk.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
A serious adverse event is defined by the Food and Drug Administration (FDA) as resulting “in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.” This definition is found in Title 21, §312.32 of the Electronic Code of Federal Regulations, which can be accessed at the following link: http://www.ecfr.gov/cgi-bin/text-idx?SID=6b68426ec6d55c78a6799d161 ba6754c&mc=true&node=se21.5.312_132&rgn=div8
References
MacNeil, J.R., et al., Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep, 2015. 64(41): p. 1171–6.
Patton, M.E., et al., Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep, 2017. 66(19): p. 509–513.
Epidemiology and Prevention of Vaccine-Preventable Diseases, Hamborsky J, Kroger A, Wolfe S, eds. 2015, Centers for Disease Control and Prevention: Washington D.C.
GlaxoSmithKline. Menhibrix Discontinuation Notice. 2016; Available from: https://www.gskdirect.com/medias/Menhibrix-Discontinuation-Notice.pdf?context=bWFzdGVyfHJvb3R8NTIyNzQxfGFwcGxpY2F0aW9uL3BkZnxoZTMvaDg1Lzg4NTg3MTMwNjM0NTQucGRmfGYxMjAyMDFmMmU2YjAwYzYyZmUxNWQyNTdjYmUzNjFjMTQ2MDUyODIyMjg4YWIzMTIzNjJhZTZjMWRlNjBlMzg.
Kroger, A.T., J. Duchin, and M. Vázquez. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017 [cited 2017 October]; Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
Syncope after vaccination--United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep, 2008. 57(17): p. 457–60.
Braun, M.M., P.A. Patriarca, and S.S. Ellenberg, Syncope after immunization. Arch Pediatr Adolesc Med, 1997. 151(3): p. 255–9.
Bernard, D.M., et al., The domino effect: adolescent girls' response to human papillomavirus vaccination. Med J Aust, 2011. 194(6): p. 297–300.
MacNeil, J.R., et al., Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep, 2016. 65(43): p. 1189–94.
Cohn, A.C., et al., Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2013. 62(Rr-2): p. 1–28.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dudley, M.Z. et al. (2018). Meningococcal. In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-94694-8_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94693-1
Online ISBN: 978-3-319-94694-8
eBook Packages: MedicineMedicine (R0)